Regeneron Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Regeneron Pharmaceuticals reports strong revenue growth driven by Dupixent and Eylea HD, despite a decline in Eylea sales and ongoing legal challenges.
NASDAQ
Regeneron Pharmaceuticals reported a strong Q1 2026 with increased revenues driven by Dupixent and EYLEA HD, despite a decline in EYLEA sales.
NASDAQ
Regeneron Pharmaceuticals reported increased net income and diluted EPS for Q3 2025, driven by strong Dupixent and Libtayo sales, despite a significant decline in EYLEA revenue and regulatory delays for EYLEA HD and Ordspono.
NASDAQ
10-Q: Regeneron Reports Mixed Q2 Results Amid EYLEA Sales Decline and Regulatory Delays, Dupixent Shines
Regeneron Pharmaceuticals reported a modest increase in net income and diluted EPS for the first half of 2025, driven by strong collaboration revenue, despite a significant decline in U.S. EYLEA sales and multiple regulatory setbacks for key products.
NASDAQ
Regeneron's Q1 2025 results show a slight revenue decrease year-over-year, with EYLEA HD growth partially offsetting EYLEA decline and Dupixent continuing its strong growth trajectory.
NASDAQ
Regeneron's Q3 2024 results show significant revenue growth, driven by strong sales of EYLEA HD and Dupixent, alongside increased collaboration revenue.
NASDAQ
Regeneron's second quarter results show significant revenue growth, primarily driven by increased sales of EYLEA HD and Dupixent, alongside advancements in its clinical pipeline.
NASDAQ
Regeneron's first quarter saw a slight decrease in overall revenue despite growth in some key products, alongside increased R&D spending and legal challenges.